AN2 Therapeutics Analyst Ratings
Evercore ISI Group Maintains In-Line on AN2 Therapeutics, Lowers Price Target to $2
Analysts Are Bullish on These Healthcare Stocks: AN2 Therapeutics, Inc. (ANTX), Heron Therapeutics (HRTX)
TD Cowen Remains a Buy on AN2 Therapeutics, Inc. (ANTX)
Oppenheimer Sticks to Their Hold Rating for AN2 Therapeutics, Inc. (ANTX)
Maintaining Caution: AN2 Therapeutics Hold Rating Amidst Epetraborole Trial Uncertainties
AN2 Therapeutics Analyst Ratings
Buy Rating Affirmed for AN2 Therapeutics Amidst Upcoming Catalysts and Strong Valuation Prospects
AN2 Therapeutics Analyst Ratings
AN2 Therapeutics Extends Losses as Leerink Cuts on Trial Setback
Leerink Cuts AN2 Therapeutics Stock Target to $7 From $23
AN2 Therapeutics Analyst Ratings
AN2 Therapeutics, Inc. (ANTX) Was Downgraded to a Hold Rating at JMP Securities
JMP Securities Initiates Coverage On AN2 Therapeutics With Market Outperform Rating, Announces Price Target of $30
AN2 Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX) and Vigil Neuroscience Inc (VIGL)
Analysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX), Pliant Therapeutics (PLRX) and Bolt Biotherapeutics (BOLT)
Positive Clinical Trials and Financial Stability Influence Buy Rating for AN2 Therapeutics
Promising NTM Treatment and Financial Health Lead to Buy Rating for AN2 Therapeutics, Inc.
Promising Outlook for AN2 Therapeutics, Inc.: Buy Rating Conferred Amid Anticipated Ph.2 Results and Encouraging Epetraborole Developments
No Data